This study applies a hypothesis-driven approach to examine the effects of chronic marijuana use on HIV-associated inflammation and its subsequent impacts on central nervous system function, with the goal of identifying the mechanisms through which cannabinoids modulate neurological disorders and other comorbidities in persons with HIV.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in neurocognitive function as measured by neuropsychological battery
Timeframe: baseline, 1-year follow-up, and 2-year follow-up
Change in neuronal integrity as measured by N-acetyl aspartate (NAA)
Timeframe: baseline, 1-year follow-up, and 2-year follow-up
Change in neuronal-glial interaction as measured by Glutamate + glutamine (GLX)
Timeframe: baseline, 1-year follow-up, and 2-year follow-up
Change in axonal loss and injury as measured by axonal diffusivity (AD)
Timeframe: baseline, 1-year follow-up, and 2-year follow-up
Change in demyelination or dysmyelination as measured by radial diffusivity (RD)
Timeframe: baseline, 1-year follow-up, and 2-year follow-up
Change in overall white matter integrity as measured by fractional anisotropy (FA)
Timeframe: baseline, 1-year follow-up, and 2-year follow-up
Change in inflammation-related cellularity as measured by restricted fraction (RF)
Timeframe: baseline, 1-year follow-up, and 2-year follow-up
Change in extracellular tissue edema as measured by non-restricted fraction (NF)
Timeframe: baseline, 1-year follow-up, and 2-year follow-up
Change in gray matter as measured by cortical area and thickness and cortical and subcortical volume
Timeframe: baseline, 1-year follow-up, and 2-year follow-up
Change in white matter integrity as measured by white matter tract streamline count
Timeframe: baseline, 1-year follow-up, and 2-year follow-up
Change in axonal damage was measured by neurofilament light (NfL) protein
Timeframe: baseline, 1-year follow-up, and 2-year follow-up